Media Centre
Latest press releases
-
Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension
-
Imfinzi approved in the US as first and only perioperative immunotherapy for patients with early gastric and gastroesophageal cancers
-
AstraZeneca plans $2 billion manufacturing investment in Maryland, supporting 2,600 jobs and catalysing economic growth
-
Koselugo approved in the US for adults with neurofibromatosis type 1
-
Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial
Medical Releases
These press releases are specifically for health specialist/medical media and are not for consumer press.
